Medtech Insights, Japan Interventional Oncology Device Market Report

Although the number of interventional oncology procedures is increasing marginally in Japan, this will apply to the Japanese interventional oncology market decrease due to the limited use of minimally invasive interventional oncology procedures as confirmed by Japanese guidelines, a rigorous product approval process, two-year reductions in reimbursement costs, a decreasing overall population and the increasing development of anticancer drugs.

This Medtech 360 report provides comprehensive data and analysis on the current status of the interventional oncology device market in Japan during 2019–2033.

Clinical guidelines influence the adoption of interventional oncology devices in Japan.

Which devices are preferred in clinical guidelines?

What are the latest changes in clinical guidelines and what impact do they have on the adoption of various devices in the Japanese market?

How will changing clinical guidelines affect market competition?

Reimbursement will be an important factor in the adoption of interventional oncology procedures in Japan.

What is the reimbursement scenario in the country and what impact will it have on the adoption of interventional oncology devices in this market?

Which devices are most affected by two-year reductions in reimbursement costs in this market?

Positive clinical data will play an important role in driving adoption of interventional oncology devices.

What clinical studies have been conducted recently in this market?

What is the expected impact of these clinical trials on market dynamics and device adoption?

A stringent regulatory framework and delays in device approval will impact the interventional oncology device market in Japan.

How have regulatory approval delays impacted the Japanese interventional oncology market?

What devices are expected to enter the Japanese market during the forecast period?

The market dynamics will change during the forecast period due to the expected entry of novel devices in this market.

What are the latest changes in ANGER spaces of radioembolization devices and spheres and how did these changes affect the estimated launch of these products?

Contents